相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1991
招募中
1
100.0%
暂无批准数据
- Pelareorep combined with standard-of-care therapy achieved a 33% objective response rate in second-line KRAS-mutant microsatellite-stable colorectal cancer, compared to 6-11% with standard therapy alone. - The investigational immunotherapy more than doubled both progression-free survival and overall survival compared to bevacizumab plus FOLFIRI treatment regimen. - Translational analysis revealed pelareorep enhanced KRAS-mutant-specific T-cell populations, providing mechanistic support for its precision immunotherapy approach. - Oncolytics Biotech plans to advance pelareorep into a controlled study following regulatory consultation to validate these promising signals in this difficult-to-treat patient population.
- A study of over 1.3 million breast cancer patients found that living in food deserts significantly reduces clinical trial participation rates. - Patients facing both food deserts and clinical trial deserts showed a 27% lower likelihood of trial enrollment compared to 19% for food desert residents alone. - The research demonstrates a compounding negative effect when patients live in areas with both limited healthy food access and distant trial sites. - Interventions such as establishing satellite facilities, telehealth options, and patient navigation programs could help address these systemic barriers.
- Pharmacists have evolved from traditional dispensing roles to comprehensive patient management in cancer care, particularly with novel therapies like CAR-T cell therapy and bispecific antibodies. - Patient selection has become a critical pharmacist responsibility, as not every patient qualifies for these advanced therapies and multiple treatment options require careful evaluation. - Pharmacists now proactively manage toxicities by monitoring lab results and patient symptoms, enabling dose adjustments and prophylactic interventions to maintain treatment continuity. - The expanded role includes value-based care participation, medication adherence monitoring, and close collaboration with multidisciplinary teams to optimize patient outcomes.
• The FITWISE trial (NCT06518837) is evaluating tirzepatide (Zepbound) for weight loss in patients with early-stage HR+/HER2- breast cancer, assessing its safety and tolerability alongside breast cancer treatments. • The primary endpoint of the phase 2 FITWISE trial is to determine the proportion of patients achieving at least a 5% body weight reduction by the end of the treatment course. • Secondary endpoints include monitoring the incidence of adverse events (AEs) and assessing the feasibility of tirzepatide treatment based on completion and discontinuation rates. • Preliminary assessments from the FITWISE trial have not identified any significant adverse events of concern, but continuous monitoring is in place due to the novelty of tirzepatide use in this population.
